Provectus Pharmaceuticals Inc., of Knoxville, Tenn., presented top-line data from a Phase II trial of PV-10, for metastatic melanoma at the Interdisciplinary Global Conference on Developing New Treatments for Melanoma in Munich, Germany
Teva Pharmaceutical Industries Ltd., of Jerusalem, reported top-line data from the Phase III GALA (Glatiramer Acetate Low-Frequency Administration) trial testing 40 mg/1 ml glatiramer acetate (GA 40 mg/1 ml) injection administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis patients
Top-line data showed that FX005, delivered intra-articularly to the knee, was well tolerated and resulted in prolonged improvement in joint pain and function throughout the 12-week duration of the study
Theraclone Sciences Inc., of Seattle, reported top-line data from a Phase I trial in healthy volunteers showing that TCN-032, a broadly protective, fully human monoclonal antibody in development for influenza A infections, was well tolerated throughout the study, with no dose-limiting toxicities or serious adverse events observed
S.L.A. Pharma AG, of Basel, Switzerland, reported top-line data from its Phase II study testing four doses of Nalcol, an oral formulation of naloxone (2.5 mg, 5 mg, 10 mg and 20 mg) in treating opioid-induced constipation in patients with persistent noncancer pain, showing statistical significant for increasing spontaneous bowel movements (SBM) against placebo and baseline
Top-line data from a Phase II trial of belinostat for cancer of unknown primary origin missed its primary endpoint of progression-free survival